METHODS	The primary outcome was time to disease relapse ( defined as additional disease-modifying antirheumatic drugs , 2 courses high-dose steroids , return to open-label abatacept ~ 10 mg/kg , or DAS28 ( C reactive protein ) 3.2 at two consecutive visits ) .\